Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 4/20 | 0.36 |
| ▸ | NOS3 | P29474 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779244 | 0.80 | DHFR (0.37) | — | |
| SCHEMBL21173558 | 0.75 | NOS3 (0.39) | NOS2NOS3NOS1 | |
| SCHEMBL19880575 | 0.74 | NOS3 (0.31) | NOS2NOS3 | |
| SCHEMBL3064440 | 0.74 | NOS2 (0.42) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL20621309 | 0.73 | — | — | |
| SCHEMBL11489975 | 0.72 | NOS2 (0.56) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL1433191 | 0.72 | NOS2 (0.41) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL1966363 | 0.71 | NOS2 (0.39) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL31053616 | 0.71 | NOS2 (0.39) | NOS2NOS3NOS1PDE3BPDE3A | |
| SCHEMBL28094709 | 0.71 | NOS2 (0.39) | NOS2NOS3NOS1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | NOS2 1227/4885NOS3 887/4885NOS1 1317/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | NOS2 1227/4885NOS3 887/4885NOS1 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.